Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Cash & Current Investments (2020 - 2026)

InMed Pharmaceuticals has reported Cash & Current Investments over the past 5 years, most recently at $7.0 million for Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 451.23% year-over-year to $7.0 million; the TTM value through Dec 2025 reached $7.0 million, up 451.23%, while the annual FY2025 figure was $11.1 million, 68.1% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $7.0 million at InMed Pharmaceuticals, down from $9.4 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $15.4 million in Q3 2021 and troughed at $1.3 million in Q4 2024.
  • A 5-year average of $7.6 million and a median of $7.0 million in 2025 define the central range for Cash & Current Investments.
  • Biggest five-year swings in Cash & Current Investments: crashed 88.23% in 2023 and later soared 451.23% in 2025.
  • Year by year, Cash & Current Investments stood at $11.3 million in 2021, then increased by 1.5% to $11.5 million in 2022, then crashed by 88.23% to $1.4 million in 2023, then decreased by 5.53% to $1.3 million in 2024, then soared by 451.23% to $7.0 million in 2025.
  • Business Quant data shows Cash & Current Investments for INM at $7.0 million in Q4 2025, $9.4 million in Q3 2025, and $11.1 million in Q2 2025.